News Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 17/06/2025 BST			5-day change	1st Jan Change
1,441.00 ^DKK	-2.27%		-3.61%	-3.45%

06-17	Genmab A/S, Q1 2025 Earnings Call, May 08, 2025
06-16	Genmab Says Experimental Combination Trial Shows High Response Rates in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	MT

Capital Increase in Genmab as a Result of Employee Warrant Exercise	06-17	GL
Genmab A/S, Q1 2025 Earnings Call, May 08, 2025	06-17
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons	06-17	GL
Genmab A/S - Transactions in Connection with Share Buy-back Program	06-17	AQ
Genmab A/S : has published its Articles of Association	06-16	PU
Transactions in Connection with Share Buy-back Program	06-16	GL
Genmab Says Experimental Combination Trial Shows High Response Rates in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	06-16	MT
Genmab's Epcoritamab Combination Shows High Response Rates in Cancer Patients	06-16	MT
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)	06-15	AQ
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)	06-15	GL
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)	06-15	BU
Grant of Restricted Stock Units and Warrants to Employees in Genmab	06-12	GL
Transactions in Connection with Share Buy-back Program	06-10	GL
Genmab A/S Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08:00 AM	06-09
AlphaValue/Baader Europe Keeps Genmab at Buy, Boosts Price Target on Pipeline Strength	06-09	MT
GENMAB : Beaten up share price offers an opportunity	06-06
Genmab's Rina-S shows promising efficacy in difficult-to-treat uterine cancer	06-03	FW
Sector Update: Health Care Stocks End Higher Late Afternoon	06-02	MT
Genmab A/S : Rina-S Update at ASCO 2025	06-02	PU
Genmab Says New Trial Data Shows 'Encouraging Anti-Tumor Activity' for Rinatabart Sesutecan	06-02	MT
Genmab A/S Announces Investigational Rinatabart Sesutecan (Rina-S) Demonstrates Encouraging Anti-Tumor Activity Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL-01 Trial	06-02	CI
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial	06-02	BU
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial	06-02	GL
Transactions in Connection with Share Buy-back Program	06-02	GL
RBC lowers target price for Genmab to DKK 2,000 (2,300), reiterates outperform rating - BN	05-30	FW

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GENMAB : Beaten up share price offers an opportunity

June 06, 2025 at 01:40 pm

Genmab: From now on, courage to the most patient

April 01, 2025 at 03:57 pm